Illumina

Historical price data

Illumina stands as the dominant player in the DNA sequencing market, powering genomic discoveries across research institutions, clinical laboratories, and pharmaceutical companies worldwide. With a comprehensive portfolio spanning benchtop to production-scale sequencers like the NovaSeq X Series and NextSeq systems, the company enables applications from whole genome sequencing to single-cell analysis. Illumina's technology platform drives advances in precision medicine, oncology research, reproductive health, and agricultural genomics, while their flexible financing solutions and robust support ecosystem make genomic technologies accessible to laboratories of all sizes.

Next-generation sequencing (NGS) platform using proprietary sequencing-by-synthesis (SBS) chemistry and XLEAP-SBS technology, delivering high-accuracy, high-throughput DNA and RNA sequencing across benchtop to production-scale systems.

5 drugs in pipeline, 1 in Phase 3

Total raised: $111M

Illumina maintains dominant market share in NGS but faces growing competition from Thermo Fisher Scientific, Pacific Biosciences, and Oxford Nanopore Technologies. The company differentiates through superior accuracy, comprehensive product ecosystem, and strong customer relationships, though competitors are advancing in specific niches like long-read and portable sequencing.